Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon

Raynaud's Disease Clinical Trial

Official title:

Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02683408
• Other study ID #: PVR-02
• Status: Completed
• Phase: N/A
• First received: February 12, 2016
• Last updated: August 14, 2017
• Start date: February 2016
• Est. completion date: July 2017

Study information

• Verified date: August 2017
• Source: Primus Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Diosmiplex is a product marketed for the management of diseases due to venous and microvascular dysfunction. Raynaud's phenomenon is a disorder of characterized by spasm of small arteries and impaired microvascular flow. This study will examine the effects of diosmiplex on the frequency and severity of Raynaud's episodes in susceptible people.

Description:

Raynaud's phenomenon is a disorder characterized by spasm of digital arteries leading to blanching, coldness and discomfort of the affected digit, affecting up to 3-5% of the population at some time in their lives. Raynaud's is roughly classified into primary and secondary forms. The primary form may occur without apparent cause or following such things as acute trauma, repetitive vibrating trauma or frostbite. Secondary Raynaud's occurs in association with a variety of systemic immunological diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SS) and Sjogren's syndrome. Perhaps the most severe forms are associated with systemic sclerosis, less often in SLE where severe microvascular changes can lead to digital ulcerations which are difficult to heal and produce considerable functional impairment Treatment of Raynaud's has been a significant clinical challenge. The primary modality is to avoid cold exposure. Many drug classes have been shown to have some, but highly variable and potential toxicities.

Diosmiplex is a prescription medical food product composed of the botanical based flavonoid molecule, diosmin, and a proprietary systemic blood alkalinizing agent, Alka4-complex. Diosmin has been used successfully in Europe as a drug for chronic venous insufficiency and its complications, including venous ulcers for more than 35 years. There is a large body of published literature regarding the molecular activity, clinical efficacy and safety of the active molecule in diosmin as well as its effects on the microvasculature where it has been shown to reduce inflammation, improve structural integrity, reduce capillary damage and improve capillary flow but no prospective clinical studies have been published regarding its effect in Raynaud's phenomenon. This will be the first prospective study to examine the efficacy and safety of diosmin, as diosmiplex, in both primary and secondary Raynaud's. The study will intentionally seek to enroll a subset of subjects with scleroderma with Raynaud's complicated by digital ulcers.

This will be a two (2) month randomized, double blind, placebo controlled study. Patients with either primary or secondary Raynaud's phenomenon present for at least 12 months and either untreated or inadequately controlled on therapy, defined as having at least four (4) vasospastic episodes/week, will be eligible for enrollment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: July 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• either gender, ages 18-80

• established diagnosis of primary or secondary Raynaud's phenomenon

• minimum of 4 vasospastic episodes/week

• medication specifically for Raynaud's must be stable for 30 days prior to the screening visit and must be maintained unchanged for the duration of the study medication specifically for digital ulceration must be stable for 60 days prior to the screening visit and must be maintained unchanged for the duration of the study

• not pregnant or breast feeding

• using approved method of birth control if capable of becoming pregnant (Appendix II)

• capable of reading and understanding the informed consent document

Exclusion Criteria:

• pregnant or nursing women

• any change in dose of oral medication specifically for Raynaud's or digital ulcers including, but not limited to, vasodilators, adrenergic blockers, antihypertensives, calcium channel blockers, ACE inhibitors, phosphodiesterase inhibitors (e.g., sildenofil,) endothelin receptor antagonists (e.g., bosentan), prostanoids (e.g., iloprost) within the 30 days prior to the screening visit for Raynaud's and /or 60 days for digital ulcers and during the duration of the study.

• any intravenous or intra-arterial Raynaud's therapy within 1 month prior to the screening visit

• Raynaud's secondary to mechanical (non-thermal) trauma

• concomitant use of diclofenac or metronidazole

• history of unstable coronary artery disease, chronic hepatic disease with ALT, AST, or alkaline phosphatase >1.3 time upper limit of normal for reference laboratory, renal disease with serum creatinine >2.5 or any gastrointestinal disease that could potentially interfere with absorption of the study product.

• history of substance abuse including "recreational drugs" and/or alcohol intake in excess of one unit daily. For the purposes of this study a unit of alcohol is defined as 12 ox. of beer, 6 oz. of wine or 1.5 oz. of hard liquor.

• history of any significant medical condition that, in the opinion of the investigator might put the subject at risk in this trial

• participation in another clinical trial within 30 days of the screening visit or 7 half lives of the study product, whichever is longer

Related Conditions & MeSH terms

• Raynaud Disease
• Raynaud's Disease

Intervention

Other:
• placebo
inactive placebo

Dietary Supplement:
• diosmiplex
diosmiplex is an FDA regulated medical food product

Locations

Country	Name	City	State
United States	West Virginai Research Institute	Charleston	West Virginia
United States	Henry Ford Hospital	Detroit	Michigan
United States	Altoona Center for Clinical Research	Duncansville	Pennsylvania
United States	Arthritis Treatment Center	Frederick	Maryland
United States	Diagnostic Rheumatology	Indianapolis	Indiana
United States	Science and Research Institute, Inc.	Jupiter	Florida
United States	Valerius Medical Group	Los Alamitos	California
United States	Jeffrey Alper, MD	Naples	Florida
United States	Sun Valley Arthritis Center	Peoria	Arizona
United States	Advanced Arthritis Care and Research	Scottsdale	Arizona
United States	Steven Kimmel MD	Tamarac	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Primus Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	percentage of subjects with by at least 50% reduction in number of vasospastic episodes	For each primary and secondary endpoint, the number and percentage of subjects meeting the criterion will be presented by treatment group at Week 4 and Week 8.	8 weeks
Secondary	percentage of subjects with at least 50% reduction in severity of vasospastic episodes	For each primary and secondary endpoint, the number and percentage of subjects meeting the criterion will be presented by treatment group at Week 4 and Week 8.	8 eeks